title: Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis.
abstract: OBJECTIVE
  To investigate the developmental effects of clozapine and other atypical antipsychotics on infants who were exposed to as fetus.
  
  
  METHODS
  The developmental progress of 33 infants who were exposed to clozapine as fetus was compared to 30 infants who were exposed to risperidone, olanzapine or quetiapine as fetus by assessing Apgar scoring, birth weight at birth, body weight, height, and the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) at months 2, 6 and 12 of age. Five subscale scores of BSID-III including cognitive, language, motor, social-emotional, and adaptive behavior were also compared. Student's t test and Chi-square analysis were used as appropriate. Repeated measurements were evaluated by analysis of covariance.
  
  
  RESULTS
  Of the 63 infants, 58 (92.1%) completed a 12-month study period. At the age of 2 and 6 months, mean adaptive behavior scores of BSID-III were significantly lower in clozapine-exposed infants than infants who exposed to other atypical antipsychotic at 2 and 6 months of age. More clozapine-exposed infants had delayed development (defined as the subscale score of <85) for adaptive behavior at 2 and 6 months of age. There was no difference between the two groups for cognitive, language, motor, social and emotional at 2, 6 and 12 months of age. More infants who were exposed to clozapine as fetus (25 of 33, 75.8%) had disturbed sleep and a labile state than those who were exposed to other atypical antipsychotics (8 of 30, 26.7%) during 2 months of age (P<0.001).
  
  
  CONCLUSIONS
  These results suggest that clozapine has more adaptive behavior effects on infants who were exposed to as a fetus than other atypical antipsychotics at 2 and 6 months of age.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT01479400.
authors.affiliation: Institute of Mental Health of The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road, Changsha 410011, Hunan, P.R. China; Brains Hospital of Hunan Province, 427# Renmin Middle Road (3 Duan), Changsha 410007, Hunan, P.R. China.
authors.forename: Ping
authors.initials: P
authors.lastname: Shao
authors.affiliation: Institute of Mental Health of The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road, Changsha 410011, Hunan, P.R. China.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Ou
authors.affiliation: Department of Obstetrical of The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road,Changsha 410011, Hunan, P.R. China.
authors.forename: Mei
authors.initials: M
authors.lastname: Peng
authors.affiliation: Institute of Mental Health of The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road, Changsha 410011, Hunan, P.R. China.
authors.forename: Jingping
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Institute of Mental Health of The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road, Changsha 410011, Hunan, P.R. China.
authors.forename: Jindong
authors.initials: J
authors.lastname: Chen
authors.affiliation: Institute of Mental Health of The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road, Changsha 410011, Hunan, P.R. China.
authors.forename: Renrong
authors.initials: R
authors.lastname: Wu
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001827:Body Height; D001835:Body Weight; D002657:Child Development / Q000187:drug effects*; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018811:Maternal Exposure / Q000009:adverse effects*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011297:Prenatal Exposure Delayed Effects; D012307:Risk Factors
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine